Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP
Status:
Completed
Trial end date:
2016-04-28
Target enrollment:
Participant gender:
Summary
Meropenem-vaborbactam is being compared to piperacillin-tazobactam in the treatment of adults
with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP).
Phase:
Phase 3
Details
Lead Sponsor:
Melinta Therapeutics, Inc. Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)